Ispinesib mesilate. Antimitotic drug, KSP inhibitor

Drugs of the Future

Volumn 31, Issue 9, 2006, Pages 778-787

  Sorbera, L A ^a   Bolos J ^a   Serradell, N ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CHLORPROMAZINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GENISTEIN; ISPINESIB; KINESIN; KINESIN SPINDLE PROTEIN; PACLITAXEL; PENTAMIDINE ISETHIONATE; PLACEBO; SB 743921; TAXANE DERIVATIVE; VINCA ALKALOID;

ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CENTROSOME; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INJECTION SITE PAIN; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MITOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TRANSAMINITIS; TUMOR REGRESSION; VOMITING;

EID: 33845315232     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.09.1034213     Document Type: Article

References (44)

1. Bergnes, G., Ha, E., Yiannikouros, G., Welday, K.A. Jr., Kalaritis, P., Yonce, B.E. (Cytokinetics Inc.; GlaxoSmithKline Inc.). Syntheses of quinazolinones. CA 2475879, EP 1480980. JP 2005529076, US 2004067969, WO 03070701.
2. Prous Science Disease Briefings: Breast Cancer (online publication). Updated September 8, 2006.
3. Garber, K. Divide and conquer: New generation of drugs targets mitosis. J Natl Cancer Inst 2005, 97(12): 874-6.
4. Hotta, K., Ueoka, H. New cytotoxic agents: A review of the literature. Crit Rev Oncol/Hemtaol 2005, 55(1): 45-65.
5. Kim, A.J., Endow, S.A. A kinesin family tree. J Cell Sci 2000, 113(21): 3681-2.
6. Endow, S.A. Microtubule motors in spindle and chromosome motility. Eur J Biochem 1999, 262(1): 12-8.
7. Turner, J., Anderson, R., Guo, J., Beraud, C., Fletterick, R., Sakowicz, R. Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker. J Biol Chem 2001, 276(27): 25496-502.
8. DeBonis, S., Simorre, J.P., Crevel, I. et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 2003, 42(2): 338-49.
9. Marcus, A.I., Peters, U., Thomas, S.L., Garrett, S., Zelnak, A., Kapoor, T.M., Giannakakou, P. Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. J Biol Chem 2005, 280(12): 11569-77.
10. Sakowicz, R., Finer, J.T., Beraud, C. et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004, 64(9): 3276-80.
11. Kapoor, T.M., Mayer, T.U., Coughlin, M.L., Mitchison, T.J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitoic kinesin, Eg5. J Cell Biol 2000, 150(5): 975-88.
12. Johnson, R.K., McCabe, F.L., Caulder, E. et al. SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenogfafts. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 1335.
13. Zhang, B., Senator, D., Wilson, C.J., Ng, S.-C. Development of a high-throughput robotic fluorescence-based assay for HsEg5 inhibitor screening. Analyt Biochem 2005, 345(2): 326-35.
14. Davis, D.A., Sarkar, S.H., Hussain, M., Li, Y., Sarkar, F.H: Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006, 6: 22-30.
15. Sutton, D., Zhang, S.Y., Gilmartin, A.G., Wood, K.W., Jackson, J.R., Huang, P.S. Mitotic arrest in tumors as a pharmacodynamic marker for inhibition of the mitotic kinesin KSP by ispinesib, a novel KSP inhibitor. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C196.
16. Jackson, J., Gilmartin, A.G., Williams, T. et al. A pharmacodynamic marker of mitosis demonstrates the antimitotic activity of SB-715992, an inhibitor of the mitotic kinesin KSP. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 1336.
17. Sutton, D., Diamond, M., Onori, J. et al. Cisplatin enhances the activity of ispinesib, a novel KSP inhibitor, against murine P388 lymphocytic leukemia. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C204.
18. Gonzales, P., Boehme, M., Bienek, A. et al. Breadth of antitumor activity of CK0238273 (SB-715992), a novel inhibitor of the mitotic kinesin KSP. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 1337.
19. Jackson, J.R., Auger, K.R., Gilmartin, A.G. et al. A resistance mechanism for the KSP inhibitor ispinesib implicates point mutations in the compound binding site. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C207.
20. Chu, Q., Holen, K.D., Rowinsky, R.K. et al. A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients (pts ) with solid tumors. Proc Am Soc Clin Oncol (ASCO) 2003, 22: Abst 525.
21. Burris, H. III, LoRusso, P., Jones, S. et al. A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. Eur J Cancer - Suppl 2003, 1(Suppl. 5): Abst 570.
22. Chu, Q.S., Holen, K.D., Rowinsky, E.K. et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Am Soc Clin Oncol (ASCO) 2004, 23: Abst 2078.
23. Heath, E.I., Alousi A., Eder, J.P. et al. A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 2026.
24. Burris, H.A., Lorusso, P., Jones, S. et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 16 q 28 days. Proc Am Soc Clin Oncol (ASCO) 2004, 23: Abst 2004.
25. Sutton, D., Zhang, S., Diamond, M. et al. Relationship between the antitumor activity of ispinesib, a novel KSP inhibitor, and neutropenia in a human xenograft model. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C203.
26. Williams, D., Kathman, S., Chu, Q. et al. A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: Pharmacokinetic (PK)/pharmacodynamic (PD) modeling of absolute neutrophil counts (ANC). Eur J Cancer - Suppl [16th AACR-NCI-EORTC Symp Mol Targets Cancer Ther (Sept 28-Oct 1, Geneva) 2004] 2004, 2(8): Abst 55.
27. Blagden, S., Seebaran, A., Molife, R. et al. Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C80.
28. Jones, S.F., Plummer, E.R., Burris, H.A. et al. Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 2027.
29. Calvo, E., Chu, Q., Till, E. et al. Phase I study of ispinesib (SB-715992) in combination with capecitabine in patients with advanced solid tumors. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C85.
30. Miller, K., Ng, C, Ang, P. et al. Phase II, open label study of SB-7815992 (ispinesib) in subjects with advanced or metastatic breast cancer. 28th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio) 2005, Abst 1089.
31. El-Khoueiry, A.B., Iqbal, S., Singh, D.A. et al. A randomized phase II non-comparative study of ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 3595.
32. Ispinesib fails to meet advancement criteria in platinum-sensitive NSCLC. DailyDrugNews.com April 4, 2006.
33. Study of ispinesib in subjects with breast cancer (NCT00089973). ClinicalTrials.gov Web site 2006.
34. Ispinesib in subjects with platinum-taxane-refractory or resistant relapsed ovarian cancer (NCT00097409). ClinicalTrials.gov Web site 2006.
35. SB-715992 in treating patients with advanced or metastatic colorectal cancer (NCT00103311). ClinicalTrials.gov Web site 2006.
36. SB-715992 in treating patients with recurrent or metastatic head and neck cancer (NCT00095628). ClinicalTrials.gov Web site 2006.
37. SB-715992 in treating patients with metastatic prostate cancer that did not respond to docetaxel or paclitaxel (NCT00096499). ClinicalTrials.gov Web site 2006.
38. SB-715992 in treating patients with metastatic or recurrent malignant melanoma (NCT00095953). ClinicalTrials.gov Web site 2006.
39. SB-715992 in treating patients with locally advanced, recurrent, or metastatic liver cancer (NCT00095992). ClinicalTrials.gov Web site 2006.
40. SB-715992 in treating patients with acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes (NCT00098826). ClinicalTrials.gov Web site 2006.
41. SB-715992 in treating patients with metastatic or unresectable solid tumors or Hodgkin's or non-Hodgkin's lymphoma (NCT00101244). ClinicalTrials.gov Web site 2006.
42. Ispinesib in combination with capecitabine in patients with solid tumors (NCT00119171). ClinicalTrials.gov Web site 2006.
43. Ispinesib in combination with docetaxel in patients with solid tumors (NCT00169520). ClinicalTrials.gov Web site 2006.
44. Ispinesib in combination with carboplatin in patients with solid tumors (NCT00136578). ClinicalTrials.gov Web site 2006.